Renata expands global footprint with Turkey regulatory approval

Renata PLC has announced that its Rajendrapur General Facility has received regulatory approval from the Turkish Medicines and Medical Devices Agency, enabling the company to register and supply oral solid dosage pharmaceutical products, including tablets and capsules, in Türkiye.

The approval marks a significant milestone for Renata as it seeks to expand its presence in the Middle East and Europe, with Türkiye positioned as a strategically important market connecting both regions. Company officials stated that the approval will facilitate access to the Turkish market and support the supply of quality-assured oral medicines to address the country's healthcare needs.

Renata noted that its Rajendrapur General Facility already holds approvals from other stringent regulatory authorities, including EU GMP and the US Food and Drug Administration (FDA), underscoring the company's commitment to maintaining global quality standards.

In a related development, Renata stated it expects regulatory approval for Amantadine in Türkiye within the next year. The antiparkinsonian drug has already been launched and commercialised by the company in several strictly regulated markets, including the United Kingdom and Nordic countries. The product is expected further to strengthen Renata's position in the Turkish pharmaceutical market.